Skip to main content
SpringerLink
Log in

NICE supports AllTrials campaign

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. this stipulates that companies are required to register a trial within 21 days of the first patient being admitted, and post the results within one year of marketing authorisation

  2. Roche has been central to this issue because of its non-release of all data on oseltamivir [Tamiflu]; see PharmacoEconomics & Outcomes News 669 p2; 801085642

References

  1. Limb M. NICE joins campaign for full disclosure of clinical trial data. BMJ : 25 Feb 2013. Available from: URL: http://dx.doi.org/10.1136/bmj.f1269

    Google Scholar 

  2. Pharma Times. Pharma industry and doctors go head-to-head on data transparency. Pharma Times : 27 Feb 2013. Available from: URL: http://www.pharmatimes.com

  3. ABPI. ABPI announces new clinical trial transparency measures. Media Release : 27 Feb 2013. Available from: URL: http://www.abpi.org.uk

  4. Kmietowicz Z. Roche says it will not relinquish control over access to clinical trial data. BMJ : 28 Feb 2013. Available from: URL: http://dx.doi.org/10.1136/bmj.f1374

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE supports AllTrials campaign. PharmacoEcon Outcomes News 673, 3 (2013). https://doi.org/10.1007/s40274-013-0196-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0196-x

Search

Navigation